Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Ieq Capital LLC

Ieq Capital LLC raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 469.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,398 shares of the biopharmaceutical company's stock after purchasing an additional 26,708 shares during the period. Ieq Capital LLC's holdings in Intra-Cellular Therapies were worth $2,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. True Wealth Design LLC bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC grew its holdings in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at $74,000. Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in Intra-Cellular Therapies during the 3rd quarter worth $97,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ITCI shares. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Piper Sandler reaffirmed a "neutral" rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. StockNews.com began coverage on Intra-Cellular Therapies in a research note on Monday. They set a "hold" rating on the stock. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $106.08.

Intra-Cellular Therapies Stock Down 0.1 %

Shares of Intra-Cellular Therapies stock traded down $0.12 during mid-day trading on Wednesday, reaching $128.46. 1,595,802 shares of the stock traded hands, compared to its average volume of 3,977,656. The stock has a market capitalization of $13.66 billion, a PE ratio of -147.65 and a beta of 0.72. The business has a 50-day moving average of $111.97 and a 200 day moving average of $90.60. Intra-Cellular Therapies, Inc. has a fifty-two week low of $63.30 and a fifty-two week high of $129.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Insider Activity at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.